Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy

• by Kanticha Thammagul, Suppalux Limpiwattakee, Pichika Chantrathammachart, Teeraya Puavilai, Suporn Chuncharunee, Pimjai Niparuck

• September 26, 2026

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

• by

• September 24, 2026

• 11 min

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia

• by Paul J. Hampel, Ying Huang, John N. Allan, Seema A. Bhat, David Bond, Danielle M. Brander, John C. Byrd, Julio C. Chavez, Elise Chong, Alexey Danilov, Matthew S. Davids, Kaitlyn Dvorak-Kornaus, Hannah Freedman, Nikita Malakhov, Matthew Matasar, Cecelia Miller, Sarah Miller, Zulfa Omer, Sameer A. Parikh, Erin M. Parry, Kari G. Rabe, Phil Raess, Manoj Rai, Joanna M. Rhodes, Kerry A. Rogers, Aditi Saha, Jake Schade, Geoffrey Shouse, Stephen Spurgeon, Deborah Stephens, Yucai Wang, Jennifer A. Woyach, Max Yano, Adam S. Kittai

• September 26, 2026

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

• by Oren Pasvolsky, Bruno Almeida Costa, Yosra M. Aljawai, Krina K. Patel, Qaiser Bashir, Dawen Sui, Samer A. Srour, Mark R. Tanner, Uday R. Popat, Neeraj Y. Saini, Chitra Hosing, Jeremy L. Ramdial, Hans C. Lee, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Guilin Tang, Robert Z. Orlowski, Richard E. Champlin, Yago Nieto, Elizabeth J. Shpall, Muzaffar H. Qazilbash

• September 26, 2026